220 related articles for article (PubMed ID: 31402481)
1. An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints.
Guo B; Liu S
Biom J; 2020 Mar; 62(2):339-349. PubMed ID: 31402481
[TBL] [Abstract][Full Text] [Related]
2. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
Zhou H; Lee JJ; Yuan Y
Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563
[TBL] [Abstract][Full Text] [Related]
3. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy.
Lin R; Coleman RL; Yuan Y
J Natl Cancer Inst; 2020 Jan; 112(1):38-45. PubMed ID: 30924863
[TBL] [Abstract][Full Text] [Related]
4. Bayesian optimal phase II clinical trial design with time-to-event endpoint.
Zhou H; Chen C; Sun L; Yuan Y
Pharm Stat; 2020 Nov; 19(6):776-786. PubMed ID: 32524679
[TBL] [Abstract][Full Text] [Related]
5. Using short-term endpoints to improve interim decision making and trial duration in two-stage phase II trials with nested binary endpoints.
Zocholl D; Kunz CU; Rauch G
Stat Methods Med Res; 2023 Sep; 32(9):1749-1765. PubMed ID: 37489267
[TBL] [Abstract][Full Text] [Related]
6. Bayesian optimal phase II designs with dual-criterion decision making.
Zhao Y; Li D; Liu R; Yuan Y
Pharm Stat; 2023; 22(4):605-618. PubMed ID: 36871961
[TBL] [Abstract][Full Text] [Related]
7. A randomized Bayesian optimal phase II design with binary endpoint.
Ding Y
J Biopharm Stat; 2023 Mar; 33(2):151-166. PubMed ID: 35793222
[TBL] [Abstract][Full Text] [Related]
8. Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints.
Yu Z; Ramakrishnan V; Meinzer C
J Biopharm Stat; 2019; 29(2):306-317. PubMed ID: 30763151
[TBL] [Abstract][Full Text] [Related]
9. A flexible design for advanced Phase I/II clinical trials with continuous efficacy endpoints.
Mozgunov P; Jaki T
Biom J; 2019 Nov; 61(6):1477-1492. PubMed ID: 31298770
[TBL] [Abstract][Full Text] [Related]
10. Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach.
Kopp-Schneider A; Wiesenfarth M; Witt R; Edelmann D; Witt O; Abel U
Biom J; 2019 May; 61(3):488-502. PubMed ID: 30175405
[TBL] [Abstract][Full Text] [Related]
11. A predictive probability interim design for phase II clinical trials with continuous endpoints.
Liu M; Dressler EV
Stat Med; 2018 May; 37(12):1960-1972. PubMed ID: 29611211
[TBL] [Abstract][Full Text] [Related]
12. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.
Zhou Y; Lee JJ; Yuan Y
Stat Med; 2019 Dec; 38(28):5299-5316. PubMed ID: 31621952
[TBL] [Abstract][Full Text] [Related]
13. Bayesian enhancement two-stage design for single-arm phase II clinical trials with binary and time-to-event endpoints.
Shi H; Yin G
Biometrics; 2018 Sep; 74(3):1055-1064. PubMed ID: 29466612
[TBL] [Abstract][Full Text] [Related]
14. Seamless phase 2/3 design for trials with multiple co-primary endpoints using Bayesian predictive power.
Yang J; Li G; Yang D; Wu J; Wang J; Gao X; Liu P
BMC Med Res Methodol; 2024 Jan; 24(1):12. PubMed ID: 38233758
[TBL] [Abstract][Full Text] [Related]
15. A Bayesian basket trial design that borrows information across strata based on the similarity between the posterior distributions of the response probability.
Fujikawa K; Teramukai S; Yokota I; Daimon T
Biom J; 2020 Mar; 62(2):330-338. PubMed ID: 31608505
[TBL] [Abstract][Full Text] [Related]
16. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
17. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
Teramukai S; Daimon T; Zohar S
Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
[TBL] [Abstract][Full Text] [Related]
18. Predictive probability of success using surrogate endpoints.
Saint-Hilary G; Barboux V; Pannaux M; Gasparini M; Robert V; Mastrantonio G
Stat Med; 2019 May; 38(10):1753-1774. PubMed ID: 30548627
[TBL] [Abstract][Full Text] [Related]
19. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
20. BOB: Bayesian optimal design for biosimilar trials with co-primary endpoints.
Chi X; Yu Z; Lin R
Stat Med; 2022 Nov; 41(26):5319-5334. PubMed ID: 36127794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
